Today we announced that we have entered into an exclusive distribution agreement with the Tamer Group (“Tamer”). The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity’s branded regenerative biomaterial products in Saudi Arabia.
Today we announced that we have entered into an exclusive distribution agreement with the Tamer Group (“Tamer”). The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity’s branded regenerative biomaterial products in Saudi Arabia.
Today we announced that we have entered into an exclusive territory distribution agreement with CH Trading Group. CH Trading Group will act as the exclusive territories distributor of Celularity’s previously announced Halal-Certified products within more than 100 countries. The Product Distribution Agreement for Celularity’s Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.
Today we announced the appointment of Paul Graves as Chief Communications Officer. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry.
Today we announced the appointment of Paul Graves as Chief Communications Officer. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry.
Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-up and Pipeline Prioritization of Next-Generation Product Candidates
Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia
Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies
Celularity Appoints Paul Graves as Chief Communications Officer